Daily Medication Pearl: Efgartigimod alfa-fcab (Vyvgart)

Article

Efgartigimod alfa-fcab (Vyvgart) is a human immunoglobulin G1 antibody fragment indicated for the treatment of generalized myasthenia gravis.

Medication Pearl of the Day: Efgartigimod alfa-fcab (Vyvgart)

Indication: Efgartigimod alfa-fcab (Vyvgart)is a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor antibody positive.

Insight:

  • Dosing: The recommended dosage is 10 mg/kg administered as an intravenous infusion over 1 hour once weekly for 4 weeks.
  • Dosage forms: Injection 400 mg in 20 mL (20 mg/mL) single-dose vial.
  • Adverse events: Most common adverse reactions (≥ 10%) in patients treated with gMG are respiratory tract infections, headache, and urinary tract infection.
  • Mechanism of action: Efgartigimod alfa-fcab is a human immunoglobulin G1 (IgG1) antibody fragment that binds to the neonatal Fc receptor, resulting in the reduction of circulating IgG.
  • Manufacturer: Argenx

Sources:

vyvgart-prescribing-information.pdf (argenx.com)

Buy Vyvgart (efgartigimod alfa-fcab) Online • Price & Costs | TheSocialMedwork

Related Videos
pharmacy oncology, Image Credit: © Konstantin Yuganov - stock.adobe.com
Mayo Clinic oncology pharmacy
Testicular cancer and prostate cancer concept. | Image Credit: kenchiro168 - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Bottle and scattered pills on color background, top view | Image Credit: New Africa - stock.adobe.com
pharmacy | Image Credit: Diego Cervo - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.